InfuSystem INFU · Analysis & News
Heads-up: USD Core CPI y/y is due in 5 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD CPI y/y is due in 5 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD Core CPI m/m is due in 5 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD CPI is due in 5 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD CPI m/m is due in 5 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD Core CPI n.s.a. m/m is due in 5 h (high impact). The outlook can shift noticeably around it.
Heads-up: USD Core CPI is due in 5 h (high impact). The outlook can shift noticeably around it.
InfuSystem stands neutral: the latest filing is an investor presentation that restates completed FY2025 results but adds no new guidance or contracts. With no price history for a technical read, there is too little fresh information to move the shares either way.
News situation · 1 items / 30 D
1 of 1 straight from the issuer or regulator
Outlook for InfuSystem Holdings
Direction, typical moves and upcoming dates from our own price, news and calendar data, recalculated on every visit. An assessment, not investment advice.
What drives it
- Restated FY2025 results show net revenue of $143.4M, up 6% year on year, with steady business growth.
- Adjusted EBITDA of $31.5M, up 25% year on year, points to improving profitability.
- Liquidity of $58.2M and a long-term Adjusted EBITDA margin target of 22%-25% suggest a solid footing.
What argues against it
- The presentation only restates known FY2025 figures, so it gives the market little new to act on.
- It contains no new guidance, contracts or binding commitments that could reprice INFU shares.
- Without price data, the technical side cannot confirm or challenge the fundamental picture.
What would change the picture
- New guidance, a contract win or updated targets from the company would give the shares a fresh catalyst.
- Incoming US inflation and jobs releases could shift broad market sentiment, though with no fixed direction for the stock.
Coming up
- US: Consumer prices · expected 2.8%, previous 2.6%
- US: Jobless claims
Economic data for INFU
Full calendarComing up
- TodayUSDCore CPI y/y●●●Forecast 2.8%Previous 2.6%in 5h
- TodayUSDCPI y/y●●●Forecast 4.2%Previous 3.7%in 5h
- TodayUSDCore CPI m/m●●●Forecast 0.2%Previous 0.3%in 5h
- TodayUSDCPI●●●Forecast 338.683Previous 336.298in 5h
- TodayUSDCPI m/m●●●Forecast 0.5%Previous 0.6%in 5h
- TodayUSDCore CPI n.s.a. m/m●●●Previous 0.4%in 5h
- TodayUSDCore CPI●●●Forecast 339.796Previous 338.896in 5h
- November 12, 2026USDInitial Jobless Claims●●●in 2 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
Both worlds over time
Technical and news signals of the last 30 days on one timeline.
What is being reported about INFU
Frequently asked questions about InfuSystem Holdings
What did InfuSystem just announce?
An investor presentation restating completed FY2025 results: net revenue of $143.4M (up 6% year on year), Adjusted EBITDA of $31.5M (up 25%), operating cash flow of $24.4M and $58.2M in liquidity. It repeats known figures rather than revealing anything new.
Why is the verdict only neutral despite good results?
The results are solid, but they were already public. A presentation that restates the past year with no new guidance or contracts gives the market little reason to reprice the shares. On top of that, the absence of price data means no technical confirmation either way.
What would change the picture for INFU?
Fresh company news would: new guidance, a contract announcement or a move toward the stated 22%-25% margin target. Broader US inflation and jobs data due shortly could also sway sentiment, though it sets only a backdrop rather than a fixed direction for the stock.
📝 Overview Generated automatically
INFU has been the subject of 1 signals across 1 articles in the last 365 days. Sentiment skews Neutral (100%).
Breakdown: 0 bullish, 0 bearish, 1 neutral.
Most-cited catalysts: Restated FY2025 metrics: net revenue $143.4M (+6% YoY), Adjusted EBITDA $31.5M (+25% YoY) (1×), $58.2M liquidity and long-term Adjusted EBITDA margin target of 22%-25% (1×). Most-cited risk factors: Presentation contains only forward-looking statements with no new quantified outlook or binding commitments (1×).